{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T08:23:06Z","timestamp":1773044586072,"version":"3.50.1"},"reference-count":5,"publisher":"BMJ","license":[{"start":{"date-parts":[[2024,6,27]],"date-time":"2024-06-27T00:00:00Z","timestamp":1719446400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.bmj.com\/company\/legal-information\/terms-conditions\/legal-information\/tdm-licencepolicy"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ"],"DOI":"10.1136\/bmj.q1440","type":"journal-article","created":{"date-parts":[[2024,6,27]],"date-time":"2024-06-27T16:31:56Z","timestamp":1719505916000},"page":"q1440","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":3,"title":["NICE recommends new gene therapy for adults with haemophilia B"],"prefix":"10.1136","author":[{"given":"Gareth","family":"Iacobucci","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2024,6,27]]},"reference":[{"key":"2024062713300595000_385.jun27_16.q1440.1","unstructured":"NICE. Final draft guidance: etranacogene dezaparvovec for treating moderately severe or severe haemophilia B [ID3812]. Jun 2024. https:\/\/www.nice.org.uk\/guidance\/indevelopment\/gid-ta10699\/documents"},{"key":"2024062713300595000_385.jun27_16.q1440.2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n653"},{"key":"2024062713300595000_385.jun27_16.q1440.3","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.p370"},{"key":"2024062713300595000_385.jun27_16.q1440.4","unstructured":"NICE. Draft guidance consultation: Etranacogene dezaparvovec for treating moderately severe or severe haemophilia B. Aug 2023. https:\/\/www.nice.org.uk\/guidance\/gid-ta10699\/documents\/draft-guidance"},{"key":"2024062713300595000_385.jun27_16.q1440.5","unstructured":"NHS England. Innovative Medicines Fund https:\/\/www.england.nhs.uk\/medicines-2\/innovative-medicines-fund\/#does-the-innovative-medicines-fund-reimburse-any-additional-costs-e-g-preparatory-implementation-associated-with-a-medicine"}],"container-title":["BMJ"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/data.bmj.org\/tdm\/10.1136\/bmj.q1440","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmj.q1440","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,27]],"date-time":"2024-06-27T20:30:35Z","timestamp":1719520235000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.bmj.com\/lookup\/doi\/10.1136\/bmj.q1440"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,27]]},"references-count":5,"alternative-id":["10.1136\/bmj.q1440"],"URL":"https:\/\/doi.org\/10.1136\/bmj.q1440","relation":{},"ISSN":["1756-1833"],"issn-type":[{"value":"1756-1833","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,27]]}}}